Instil Bio(TIL) - 2025 Q2 - Quarterly Results

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 ("'2510") anticipated before the end of 2025 Updated '2510 monotherapy data in squamous-NSCLC to be presented at IASLC's 2025 World Conference on Lung Cancer (WCLC) by ImmuneOnco DALLAS, TX, August 13, 2025 (GLOBE NEWSWIRE) Instil Bio, Inc. ("Instil") (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing ...